Clinical Trial Budget Drivers Every Device Startup Should Track

Written by Julio Martinez-Clark in Uncategorized

Clinical Trial Budget Drivers Every Device Startup Should Track

Updated October 5, 2026

A clinical trial budget for a first-in-human medical device study spans eight interconnected workstreams: regulatory strategy, ethics and regulatory approvals, site activation, per-patient costs, enrollment and screen failures, data management, safety monitoring, and the clinical study report. Each driver interacts with the others, and underestimating any one creates overruns that compress the runway available for the next funding milestone. This guide breaks down each cost driver, explains how the drivers interact, and shows how geography and program structure decisions made early either compound or contain the total. Use it to build a budget before you issue an RFP, not to rationalize one after the fact.

Most founders anchor their clinical trial budget on a single number and build everything else around it. That framing fails before the first patient is screened. Knowing what each driver costs, and how it interacts with the others, is what lets you catch overruns before they happen.

Why FIH Clinical Trial Budgets Are Hard to Estimate Early

The most common anchoring mistake is treating the CRO management fee as the budget. The management fee is one component. Regulatory strategy, ethics approvals, site activation, enrollment, data management, safety monitoring, and submission preparation are separate cost centers that together typically exceed the management fee. A founder who prices only the CRO fee and estimates everything else as a rounding error will run out of money before hitting the enrollment target.

The second structural problem is workstream interaction. These eight cost drivers do not sit in parallel. They compound. An approval delay does not just push the timeline out by one month. It adds a month of overhead across every active workstream: staff salaries, device inventory carrying costs, site readiness maintenance, and sponsor operations. A screen failure rate that is higher than modeled does not just add a few screening visits. It extends the enrollment window, which extends every downstream cost that scales with time.

The third problem is benchmark selection. U.S. and EU trial infrastructure is built for large pharma programs: multi-site Phase III studies with enterprise data systems, centralized ethics review boards, and site networks sized for hundreds of patients. When a startup with a lean FIH budget receives a quote built on that infrastructure, the numbers rarely fit, and neither does the timeline. Using U.S. infrastructure as the default benchmark leads to either sticker shock that kills the program or a scope reduction that produces data FDA cannot use.

Understanding where cost actually accumulates, and how each driver interacts with the others, is the prerequisite for building a budget that survives contact with reality.

The Eight Cost Drivers in a Medical Device FIH Study

1. Regulatory Strategy and Pre-Submission Work

Before a single patient is enrolled, you need a clear FDA pathway and a protocol that will generate data FDA will accept. That means FDA Pre-Sub meetings, IDE preparation where applicable, and protocol architecture aligned to your intended 510(k), De Novo, PMA, or HDE route.

Regulatory strategy is consistently underbudgeted because it feels like planning rather than execution, but a protocol misalignment forces mid-study amendments that cost both time and money. A protocol rework after site activation can set a program back by months, which in startup terms means another quarter of overhead without data.

Solid regulatory strategy at the front end is one of the most cost-efficient investments in the entire budget. bioaccess® anchors regulatory strategy to the sponsor's intended U.S. FDA pathway from day one, across all nine workstreams of the FIH-12™ program, so the evidence package is submission-ready without rework at the end.

2. Ethics and Regulatory Approval Timelines

Approval timelines directly affect burn rate. Every month a study sits in a regulatory queue is a month of overhead: staff salaries, device inventory carrying costs, site readiness maintenance, and deferred data.

In the U.S. and EU, ethics and regulatory approvals typically take 6 to 12 months. In Panama, El Salvador, Chile, and the Dominican Republic, the same approvals are observed in 30 to 90 days. That gap is not a logistics preference. It is a material budget variable. A startup maintaining a standing team while waiting on approvals accumulates overhead that reduces the capital available for actual clinical execution.

3. Site Activation and Investigator Fees

Site activation covers site qualification, contract negotiation, Ethics Committee submissions at the site level, and investigator training. For a multi-site study, these costs multiply.

Investigator fees vary by country and specialty. Device trials requiring surgical implantation or specialized procedural skills command higher per-procedure fees than simpler interventional studies. Budgeting accurately here requires knowing your device category, the investigator profile your protocol demands, and the site's patient volume in your target indication.

Working with a network of pre-qualified sites reduces activation time and lowers the cost of feasibility work. bioaccess® operates across 50-plus pre-qualified sites in 19 Latin American and Caribbean markets, which means that infrastructure does not need to be rebuilt from scratch for each new sponsor. That translates directly into lower activation cost and faster time to first patient.

4. Per-Patient Costs

Per-patient cost is the line item that most clearly separates U.S. and EU trial execution from Latin American execution. In the U.S., per-patient costs for a FIH device study routinely reach six figures when you include site fees, investigator fees, protocol-required diagnostics, and patient management. That cost structure is incompatible with a lean FIH budget unless your sample size is very small.

In Panama, per-patient costs under the FIH-12™ program cover the clinical work at the site level and reflect the cost structure of a pre-qualified site operating under ISO 14155 and FDA 21 CFR Part 812.28. Costs vary across other markets in the 19-country network.

5. Patient Enrollment and Screen Failure Rates

Enrollment is where most FIH budgets experience their largest unplanned overruns. The primary causes are overly optimistic enrollment rate assumptions and underestimated screen failure rates.

Eligibility criteria in medical device FIH studies tend to be narrow. You may need a specific anatomical profile, a defined disease severity range, or a prior treatment history. Screen failure rates of 30 to 50 percent are common in device studies. If your budget assumes a one-to-one screening-to-enrollment ratio, you will run out of money before hitting your sample size.

Enrollment costs include patient stipends, screening visits, protocol-required diagnostics, and site staff time per patient contact. Site selection decisions made at the protocol design stage, not after site activation, are the most effective lever for managing enrollment cost.

6. Data Management and Electronic Data Capture

Electronic data capture (EDC) setup, data entry, query resolution, and database lock are both fixed and variable costs that scale with protocol complexity and visit count. A lean protocol with fewer endpoints and fewer visits costs less to manage than a heavily instrumented study.

This is worth considering at the protocol design stage. Every additional data collection point adds EDC configuration time, site training time, and query volume. A protocol with 40 data fields per visit costs meaningfully more to manage than one with 20, and that difference compounds across every patient and every visit.

Data collected under ISO 14155 and structured per FDA 21 CFR Part 812.28 is accepted for U.S. IDE and IND submissions. That standard matters for budget planning because it determines whether data collected in Latin America can go directly into your FDA submission package or requires rework. Re-formatting, re-validating, or re-collecting data that was not captured to the right standard is an unplanned cost that can derail a submission timeline.

7. Safety Monitoring and Adverse Event Reporting

Safety monitoring is a fixed operational cost that scales with patient count and protocol risk classification. A Data Safety Monitoring Board (DSMB), if required, adds both direct fees and coordination overhead. Adverse event reporting obligations under GCP and ISO 14155 require trained clinical operations staff at the site level and sponsor level.

Underestimating safety monitoring costs is common in early-stage budgets because founders focus on clinical execution and treat safety infrastructure as a compliance checkbox. In practice, a serious adverse event that is not managed correctly, reported late, documented incompletely, or escalated through the wrong channel, can trigger a clinical hold or a regulatory inquiry that costs far more than the monitoring infrastructure would have.

8. Clinical Study Report and Submission Package

The clinical study report (CSR) and supporting submission package are the deliverables that justify the entire budget. A CSR that does not meet FDA's expectations for format, completeness, or statistical presentation will require revision, and revision cycles at the submission stage are expensive in both fees and time added to your regulatory timeline.

Budgeting for a submission-ready evidence package from the start, rather than treating the CSR as a post-study add-on, changes how you scope the data management and medical writing workstreams. The FIH-12™ program structures the submission package as a defined deliverable within the 12-month engagement, not a separate project that begins after database lock.

How Much Does a First-in-Human Medical Device Trial in Panama or El Salvador Cost Compared with the United States?

Per-patient costs in Panama under the FIH-12™ program cover clinical work at pre-qualified sites operating under ISO 14155 and FDA 21 CFR Part 812.28. U.S. per-patient costs for a comparable FIH device study routinely reach six figures when site fees, investigator fees, and protocol-required diagnostics are included. For a startup with a lean FIH budget, that difference is the deciding factor in whether the program is executable at all.

That approval gap, 30 to 90 days in Panama and El Salvador versus 6 to 12 months in the U.S. and EU, is the single largest carrying-cost variable in the budget. Every month in that queue adds overhead across the full program: staff, device inventory, site readiness, and sponsor operations.

The critical qualifier is data bridgeability. Running a study in Latin America only saves money if FDA accepts the data for your U.S. submission. Data collected under ISO 14155 and structured per FDA 21 CFR Part 812.28 meets that standard. The Establishment Labs case study, where LATAM clinical evidence supported FDA PMA approval for Motiva® implants, is a documented example of that pathway working at the PMA level. ClarVista Medical's trajectory, from first-in-human to Alcon acquisition, followed the same logic: FIH execution in Latin America, FDA-bridgeable data, and a clinical evidence package that supported the downstream commercial outcome.

For a deeper breakdown of how these cost differences play out across budget scenarios by device class, see How Much Does a First-in-Human Trial Cost in Latin America vs the United States? When selecting a CRO for this work, see Contract Research Organization Companies: How to Compare Them for a framework on evaluating vendors. Sponsors working in specific markets may also find these registration guides useful: How to register a medical device in the Dominican Republic with DIGEMAPS and How to register a medical device in Uruguay with MSP (single Local Holder).

How Program Structure Affects Your Clinical Trial Budget

The structure of your CRO engagement affects total cost as much as geography does. A fragmented model, where regulatory strategy, site operations, data management, and medical writing are handled by separate vendors, introduces coordination overhead, version control risk, and accountability gaps that inflate both cost and timeline.

When the team managing your FDA Pre-Sub is not the same team managing site activation and data collection, protocol amendments travel through a multi-vendor change order process. Each handoff adds time and cost. Discrepancies between what the regulatory consultant specified and what the data management vendor configured require reconciliation meetings, revised scope documents, and, in some cases, data re-collection. None of that work appears in the original budget.

Single-team accountability across all workstreams removes that overhead. Single-team accountability removes coordination overhead: amendments are handled internally, version control is a single-team problem, and discrepancies between regulatory specs and data configuration do not require cross-vendor reconciliation. That structural efficiency has a direct effect on how much of your budget reaches patient care versus administrative coordination.

The Cook Group multi-site FIH study, which involved 142-plus INVIMA regulatory submissions managed across Colombia, illustrates what operational scale looks like when site relationships and regulatory infrastructure are already in place. That infrastructure does not need to be built from scratch for each new sponsor, and the cost of not having to build it shows up directly in the budget.

For a full overview of how the nine-workstream engagement model is structured from protocol development through submission, the first-in-human trials guide covers the complete execution framework.

What Is the FIH-12 Program from bioaccess and Is It Right for Your Device Program?

The FIH-12™ program is a nine-workstream, 12-month engagement from bioaccess® that covers FDA Pre-Sub and IDE/IND pathway alignment, protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package. The program is designed for MedTech, biopharma, and radiopharma sponsors who need to move from regulatory strategy through first-in-human execution and arrive at a complete FDA submission package within a single, defined engagement.

The nine workstreams run in parallel rather than sequentially, which is how the program fits a 12-month window. Regulatory strategy and protocol development begin simultaneously. Site activation starts while Pre-Sub alignment is underway. Data management infrastructure is configured before the first patient is enrolled, not after. That parallel structure compresses the timeline without compressing the work.

The program is a full-program delivery structure, from first regulatory contact through database lock and CSR, for sponsors preparing for an FDA Pre-Sub meeting who need IDE or IND pathway alignment and a submission-ready evidence package at the end of execution.

The FIH-12™ program's defining characteristic is single-team accountability across all nine workstreams, which removes the coordination overhead that fragmented vendor models introduce. The submission package is a defined deliverable within the engagement, not a separate project scoped after data collection ends.

Intake is capped at eight new programs per quarter. That is a capacity constraint, not a marketing position. Sponsors whose IDE approval or Series A close is approaching should factor that constraint into their planning timeline. For timeline and protocol-to-LPLV detail, see the FIH-12™ protocol-to-LPLV timeline.

Common Budget Mistakes Device Startups Make

Six mistakes account for most FIH budget overruns. Each one is avoidable if it is identified before the budget is finalized.

1. Anchoring on the CRO fee alone. The management fee is one line item. Regulatory approvals, site activation, enrollment, data management, safety monitoring, and submission preparation are separate cost centers that together typically exceed the management fee.

2. Assuming U.S. approval timelines in a Latin American study. Approval speed is country-specific. A 30-to-90-day window applies in Panama, El Salvador, Chile, and the Dominican Republic. If your CRO's site network is not in those countries, that timeline does not apply to your program.

3. Using a one-to-one screening-to-enrollment ratio. Screen failure rates in device FIH studies are consistently higher than founders model. Budget for the screening visits, not just the enrolled patients.

4. Treating the CSR as a post-study project. Medical writing and submission preparation take time and cost money. If they are not scoped into the original budget, they become an unplanned cost that delays your filing.

5. Ignoring carrying costs during the approval queue. Every month between protocol finalization and first patient enrolled costs money across the full program. Staff, device inventory, site readiness, and sponsor overhead do not pause while approvals are pending.

6. Fragmenting vendors across workstreams. Coordination overhead between a regulatory consultant, a site management organization, a data management vendor, and a medical writer adds cost and risk that a single-team engagement avoids.

Building a Clinical Trial Budget That Fits Your Capital Cycle

A FIH budget that fits your capital cycle is not the cheapest budget you can build. It is the one that delivers a submission-ready evidence package within the runway your next funding milestone requires. Those are different optimization targets, and conflating them is how programs arrive at database lock with no capital left for the CSR.

Building that budget requires working through five decisions in order:

1. Model the full cost stack before you issue an RFP. Regulatory strategy, approval timeline carrying costs, site activation, per-patient costs at realistic screen failure rates, data management, safety monitoring, and submission preparation all need line items. A budget that accounts for only the CRO management fee and per-patient costs will be wrong before the first site is activated.

2. Choose geography on cost and data standards together, not cost alone. A per-patient cost advantage disappears if the data collected cannot go directly into your FDA submission package. Confirm that your CRO collects data under ISO 14155 and structures it per FDA 21 CFR Part 812.28 before you model any geographic savings.

3. Model approval timelines as a carrying-cost variable. Take the number of months between protocol finalization and expected first patient enrolled, multiply by your monthly program overhead, and add that figure to your budget. If that number is large, geography selection becomes a budget decision, not just an operational one.

4. Structure your CRO engagement for single-team accountability. Scope the submission package as a defined deliverable within the engagement, not a separate project. Confirm that the team managing regulatory strategy is the same team managing data collection.

5. Time the engagement against your next funding milestone. Map the 12-month FIH-12™ engagement window against your Series A close or IDE approval date. If those dates are close, factor in the eight-program-per-quarter intake cap when you plan your outreach. For a detailed look at how device class and protocol complexity affect the full cost picture, see Medical device clinical trial cost (2026): FIH and EFS pricing benchmarks.

FAQs

What is a clinical trial budget for a medical device FIH study?

A clinical trial budget for a first-in-human medical device study is a comprehensive cost plan covering all eight workstreams from protocol development through FDA submission: regulatory strategy and Pre-Sub work, ethics and regulatory approvals, site activation, per-patient costs, enrollment and screen failures, data management, safety monitoring, and clinical study report preparation. The CRO management fee is one component of that plan, not a proxy for the total.

Is data collected in Latin America accepted by FDA for IDE and IND submissions?

Yes, when collected under ISO 14155 and structured per FDA 21 CFR Part 812.28. That standard governs foreign clinical data acceptance for U.S. submissions. The Establishment Labs case study, where LATAM clinical evidence supported FDA PMA approval for Motiva® implants, is a documented example of that pathway working at the PMA level.

How do ethics and regulatory approval timelines affect a FIH clinical trial budget?

Directly, through carrying costs. Every month between protocol finalization and first patient enrolled is a month of overhead across the full program: staff, device inventory, site readiness, and sponsor operations. In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30 to 90 days. In the U.S. and EU, the same approvals typically take 6 to 12 months. For a startup maintaining a standing team during that wait, the gap is a material budget variable.

What screen failure rate should a device startup budget for in a FIH study?

Eligibility criteria in device FIH studies tend to be narrow, requiring specific anatomical profiles, defined disease severity ranges, or prior treatment histories. A one-to-one screening-to-enrollment assumption will produce an enrollment cost that is significantly lower than what the study actually requires, and the shortfall shows up mid-study when there is no budget left to address it.

How many programs does bioaccess accept per quarter?

Intake for the FIH-12™ program is capped at eight new programs per quarter. This is a capacity constraint that reflects the operational demands of single-team accountability across nine workstreams. Sponsors whose IDE approval or Series A close is within the next two quarters should factor that constraint into their outreach timeline.

Conclusion

A clinical trial budget fails when it is built around one number. The eight workstreams in a FIH device study interact: an approval delay extends carrying costs across every active workstream, a higher-than-modeled screen failure rate extends enrollment and every downstream cost that scales with time, and a CSR scoped as an afterthought delays the submission it was meant to support. Geography and program structure are the two largest controllable variables, and both decisions need to be made before the budget is finalized, not after the RFP goes out.

The most useful next step is to map your full cost stack against your next funding milestone. Start with approval timeline carrying costs, because that figure is often the largest unmodeled variable in early-stage FIH budgets. Then confirm that your CRO engagement structure assigns single-team accountability across all workstreams and treats the submission package as a defined deliverable. Those two decisions, geography chosen on cost and data standards together, and a single-team engagement scoped through CSR, determine whether your clinical trial budget survives contact with reality.